Yoon-Sim Yap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoon-Sim Yap has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Curigliano
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
14 shared publications Adam Crystal
13 shared publicationsAlejandro Balbin
13 shared publicationsCatherine Terret
13 shared publicationsDejan Juric
13 shared publications- Fabrice André
Gustave Roussy, Villejuif, France
13 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in The Breast
- Vol. 90
To stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission
- 12 October 2026
- Published by Elsevier in The Breast
- Vol. 90
Open AccessTo stop or not to stop? International physician survey on HER2 targeted therapy for metastatic breast cancer patients in remission
- Open Access
- 18 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA
Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer. Samples with high and ultra-low levels of tumor-derived DNA are combined into controlled dilution series that preserve the properties of authentic cell-free DNA, including each patient’s germline and blood-cell mutation backgrounds. Using deep whole-genome (150x) and exome (2,000x) sequencing, we define a reference set of ~37,000 single nucleotide variants and ~58,000 indels to benchmark nine somatic variant callers across varying ctDNA levels and sequencing depths. We also explore machine learning–based tuning of individual callers and identify features that improve accuracy in cfDNA. This benchmarking resource clarifies the detection limits of current approaches and provides practical guidance for selecting somatic variant calling methods in liquid biopsy applications.
- 18 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessComprehensive benchmarking of methods for mutation calling in circulating tumor DNA
Detection of somatic mutations in cell-free DNA (cfDNA) is challenging due to low variant allele frequencies and extensive DNA degradation. Here we develop a benchmarking strategy using longitudinal patient-matched cfDNA samples from individuals with colorectal and breast cancer. Samples with high and ultra-low levels of tumor-derived DNA are combined into controlled dilution series that preserve the properties of authentic cell-free DNA, including each patient’s germline and blood-cell mutation backgrounds. Using deep whole-genome (150x) and exome (2,000x) sequencing, we define a reference set of ~37,000 single nucleotide variants and ~58,000 indels to benchmark nine somatic variant callers across varying ctDNA levels and sequencing depths. We also explore machine learning–based tuning of individual callers and identify features that improve accuracy in cfDNA. This benchmarking resource clarifies the detection limits of current approaches and provides practical guidance for selecting somatic variant calling methods in liquid biopsy applications.
- Open Access
- 1 April 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (4) , 781-784
Risking arm lymphedema in more than a hundred patients to benefit one patient—is it worth it?
Risking arm lymphedema in more than a hundred patients to benefit one patient—is it worth it?
- 1 April 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (4) , 781-784
Open AccessRisking arm lymphedema in more than a hundred patients to benefit one patient—is it worth it?
Risking arm lymphedema in more than a hundred patients to benefit one patient—is it worth it?
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 5 shows baseline versus end-of-treatment tumor mutation status among those who achieved a defined clinical benefit on treatment.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 5 shows baseline versus end-of-treatment tumor mutation status among those who achieved a defined clinical benefit on treatment.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 1 shows LSZ102 dose proportionality analyses for fasted, once-daily administration
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 1 shows LSZ102 dose proportionality analyses for fasted, once-daily administration
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 2 shows on-treatment estrogen receptor H-score changes from baseline in the combination treatment arms.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 2 shows on-treatment estrogen receptor H-score changes from baseline in the combination treatment arms.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Data from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Purpose:Data are sparse for oral selective estrogen receptor (ER) degraders (SERD) in cancer treatment. The investigational oral SERD LSZ102 was assessed in monotherapy and combination use in a phase I study.Patients and Methods:A phase I, multicenter, open-label dose-escalation study (NCT02734615) of LSZ102 alone (arm A; n = 77) or with ribociclib (arm B; n = 78) or alpelisib (arm C; n = 43) in heavily pretreated adults with histologically confirmed ER-positive breast cancer and prior disease progression. Arm A received LSZ102 200–900 mg/day; arm B, LSZ102 200–600 mg/day plus ribociclib 300–600 mg/day; arm C, LSZ102 300–450 mg/day plus alpelisib 200–300 mg/day. Key outcomes were dose-limiting toxicities (DLT) in the first 28-day treatment cycle, adverse events (AE), laboratory parameters, pharmacokinetics, biopsy ER protein, and investigator-assessed clinical response (RECIST v1.1).Results:The most common AEs were gastrointestinal. Treatment-related serious AEs occurred in 10% of participants (19/198), mostly in arm C [10/43 (23%)]. DLTs occurred in: arm A, 5% (4/77); arm B, 3% (2/78); and arm C, 19% (8/43). LSZ102 exposure was slightly greater than dose proportional. On-treatment biopsy ER reductions were observed, with a trend toward an LSZ102 dose response. Objective response rates (95% confidence interval) were: arm A, 1.3% (0.0–7.0); arm B, 16.9% (9.3–27.1); and arm C, 7.0% (1.5–19.1), and clinical benefit rates 7.8% (2.9–16.2), 35.1% (24.5–46.8), and 20.9% (10.0–36.0), respectively.Conclusions:LSZ102 was well tolerated alone and with ribociclib and had a manageable safety profile with alpelisib. Preliminary clinical activity was observed in combination use.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Purpose:Data are sparse for oral selective estrogen receptor (ER) degraders (SERD) in cancer treatment. The investigational oral SERD LSZ102 was assessed in monotherapy and combination use in a phase I study.Patients and Methods:A phase I, multicenter, open-label dose-escalation study (NCT02734615) of LSZ102 alone (arm A; n = 77) or with ribociclib (arm B; n = 78) or alpelisib (arm C; n = 43) in heavily pretreated adults with histologically confirmed ER-positive breast cancer and prior disease progression. Arm A received LSZ102 200–900 mg/day; arm B, LSZ102 200–600 mg/day plus ribociclib 300–600 mg/day; arm C, LSZ102 300–450 mg/day plus alpelisib 200–300 mg/day. Key outcomes were dose-limiting toxicities (DLT) in the first 28-day treatment cycle, adverse events (AE), laboratory parameters, pharmacokinetics, biopsy ER protein, and investigator-assessed clinical response (RECIST v1.1).Results:The most common AEs were gastrointestinal. Treatment-related serious AEs occurred in 10% of participants (19/198), mostly in arm C [10/43 (23%)]. DLTs occurred in: arm A, 5% (4/77); arm B, 3% (2/78); and arm C, 19% (8/43). LSZ102 exposure was slightly greater than dose proportional. On-treatment biopsy ER reductions were observed, with a trend toward an LSZ102 dose response. Objective response rates (95% confidence interval) were: arm A, 1.3% (0.0–7.0); arm B, 16.9% (9.3–27.1); and arm C, 7.0% (1.5–19.1), and clinical benefit rates 7.8% (2.9–16.2), 35.1% (24.5–46.8), and 20.9% (10.0–36.0), respectively.Conclusions:LSZ102 was well tolerated alone and with ribociclib and had a manageable safety profile with alpelisib. Preliminary clinical activity was observed in combination use.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplement 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplement 2 contains the trial statistical analysis plan.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplement 2 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplement 2 contains the trial statistical analysis plan.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 3 shows progression-free survival (Kaplan-Meier) in each treatment arm.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Supplementary figure 3 shows progression-free survival (Kaplan-Meier) in each treatment arm.
- Open Access
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Information from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
The supplementary information describes the procedures used to assess circulating tumor DNA using the Novartis PanCancer gene panel.
- 4 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Information from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
The supplementary information describes the procedures used to assess circulating tumor DNA using the Novartis PanCancer gene panel.